CN103068404B - 药物多聚物微粒及其制造方法 - Google Patents

药物多聚物微粒及其制造方法 Download PDF

Info

Publication number
CN103068404B
CN103068404B CN201180027818.7A CN201180027818A CN103068404B CN 103068404 B CN103068404 B CN 103068404B CN 201180027818 A CN201180027818 A CN 201180027818A CN 103068404 B CN103068404 B CN 103068404B
Authority
CN
China
Prior art keywords
general formula
group
drug
organic
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180027818.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103068404A (zh
Inventor
笠井均
中西八郎
马场耕一
及川英俊
村上达也
今堀博
桥田充
王勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Publication of CN103068404A publication Critical patent/CN103068404A/zh
Application granted granted Critical
Publication of CN103068404B publication Critical patent/CN103068404B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201180027818.7A 2010-06-11 2011-06-07 药物多聚物微粒及其制造方法 Expired - Fee Related CN103068404B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010-133486 2010-06-11
JP2010133486 2010-06-11
PCT/JP2011/063084 WO2011155501A1 (ja) 2010-06-11 2011-06-07 薬剤多量体微粒子及びその製造方法

Publications (2)

Publication Number Publication Date
CN103068404A CN103068404A (zh) 2013-04-24
CN103068404B true CN103068404B (zh) 2015-11-25

Family

ID=45098106

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180027818.7A Expired - Fee Related CN103068404B (zh) 2010-06-11 2011-06-07 药物多聚物微粒及其制造方法

Country Status (5)

Country Link
US (1) US20130096097A1 (enExample)
EP (1) EP2586463B1 (enExample)
JP (2) JP5113958B2 (enExample)
CN (1) CN103068404B (enExample)
WO (1) WO2011155501A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150119388A1 (en) * 2012-06-15 2015-04-30 The Children's Hospital Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
JP7626491B2 (ja) * 2021-03-12 2025-02-04 国立研究開発法人科学技術振興機構 Ｓｎ－３８誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法
CN120322442A (zh) * 2022-12-09 2025-07-15 国立研究开发法人科学技术振兴机构 化合物、纳米粒子、医药、及纳米粒子的制造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141093A1 (en) * 2005-12-20 2007-06-21 Sonus Pharmaceuticals, Inc. Lipophilic di(anticancer drug) compounds, compositions, and related methods
WO2009013466A1 (en) * 2007-07-20 2009-01-29 Fujifilm Manufacturing Europe B.V. Preparation of fine particles
CN101628919A (zh) * 2009-08-20 2010-01-20 浙江大学 喜树碱及其衍生物的自乳化药物前体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JP2723200B2 (ja) 1992-09-07 1998-03-09 均 笠井 非線形光学用有機微結晶の製法
ES2262223T3 (es) 1997-02-14 2006-11-16 Bionumerik Pharmaceuticals, Inc. Derivados de camptotecina altamente lipofilos.
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
AU2003253890A1 (en) * 2002-07-12 2004-02-02 Biomarin Pharmaceutical Inc. The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
US20070041093A1 (en) 2005-08-22 2007-02-22 Stuart Bard Projector screen for use in a lighted room
US8367065B2 (en) 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
CN101541332A (zh) 2006-09-15 2009-09-23 安佐制药股份有限公司 含多官能连接基的靶向聚合物前药
CL2008003699A1 (es) * 2007-12-13 2009-10-09 Takeda Pharmaceuticals Co Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas.
WO2010053101A1 (ja) * 2008-11-06 2010-05-14 国立大学法人東北大学 眼内移行性の高い点眼剤および蛍光イメージング剤ならびにそれらの製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141093A1 (en) * 2005-12-20 2007-06-21 Sonus Pharmaceuticals, Inc. Lipophilic di(anticancer drug) compounds, compositions, and related methods
WO2009013466A1 (en) * 2007-07-20 2009-01-29 Fujifilm Manufacturing Europe B.V. Preparation of fine particles
CN101628919A (zh) * 2009-08-20 2010-01-20 浙江大学 喜树碱及其衍生物的自乳化药物前体及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Prodrugs Forming High Drug Loading Multifunctional Nanocapsules for Intracellular Cancer Drug Delivery;Youqing Shen, et al;《J. AM. CHEM. SOC.》;20100310;第132卷(第12期);第4261页Scheme 2. *
The effect of the linker on the hydrolysis rate of drug-linked ester bonds;Ronald G. Schoenmakers, et al.;《Journal of Controlled Release》;20041231;第95卷;第291–300页,尤其是摘要 *

Also Published As

Publication number Publication date
EP2586463A1 (en) 2013-05-01
EP2586463A4 (en) 2014-03-19
EP2586463B1 (en) 2016-08-17
JPWO2011155501A1 (ja) 2013-08-01
WO2011155501A1 (ja) 2011-12-15
CN103068404A (zh) 2013-04-24
JP5113958B2 (ja) 2013-01-09
US20130096097A1 (en) 2013-04-18
JP2013040189A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
EP2206502B1 (en) Polymer conjugate of steroid
CN103068404B (zh) 药物多聚物微粒及其制造方法
JP2019094260A (ja) 癌疾患治療用ナノ粒子化製剤
KR20110089151A (ko) 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
CN109021026A (zh) 顺铂药物前体、制备方法和应用
CN103720675B (zh) 一种具有氧化还原敏感的姜黄素前药胶束、胶束单体及其制备方法
JP2021147340A (ja) 化合物、そのナノ粒子及び癌疾患の治療剤
CN111484501A (zh) 羟基喜树碱亚油酸酯小分子前药及其自组装纳米粒的构建
CN108785683A (zh) 一种还原响应性药物-药物共轭体的制备方法
JP2016523915A (ja) ドセタキセルポリマーナノ粒子及びそれを使用する癌の治療方法
CN106046029A (zh) 一类还原性响应两亲性小分子前药及其制备方法
CN106474060A (zh) 具有pH和还原双重敏感的两亲三嵌段共聚物及其制备和应用
CN108836937B (zh) 顺铂纳米药物制剂、制备方法和应用
CN104478890B (zh) 一种全反式维甲酸-喜树碱类抗癌药物偶联物及其制备方法和应用
CN106236752A (zh) 联合用药抗肿瘤药物、制备方法及应用
CN107998405B (zh) 包含难溶性药物的no供体型聚合胶束组合物的制备方法及应用
CN107714641A (zh) 一种用于联合用药的喜树碱前药负载双药物超分子水凝胶的制备方法
CN106674315B (zh) 基于季戊四醇的Janus脂质及其中间体，制备方法与用途
ZA200604093B (en) Tocopherol-modified therapeutic drug compounds
Jeon et al. A versatile gold cross-linked nanoparticle based on triblock copolymer as the carrier of doxorubicin
Ahmadkhani et al. Synthesis and evaluation of a triblock copolymer/ZnO nanoparticles from poly (ε-caprolactone) and poly (Acrylic Acid) as a potential drug delivery carrier
CN116063354A (zh) 一种还原响应化疗-免疫治疗前药、纳米胶束及制备方法
Jana et al. Calixarenes containing supramolecular vehicles for drug delivery
Hu et al. Dual acid/glutathione-responsive core-degradable/shell-sheddable block copolymer nanoassemblies bearing benzoic imines for enhanced drug release
CN107674196B (zh) 一种具有抗肿瘤作用的多西紫杉醇前药及制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: Kawaguchi City, Saitama Prefecture of Japan

Patentee after: State-run research and development legal person JST

Address before: Kawaguchi City, Saitama Prefecture of Japan

Patentee before: Independent Administrative Corporation Japan Science & Tech Corp.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151125

Termination date: 20170607

CF01 Termination of patent right due to non-payment of annual fee